The Heart of the Matter: Ranking PEDs by Cardiovascular Risk

Your Heart Hates Oral Steroids. Here's Why.

Nothing in the performance-enhancing world has a clearer record of cardiovascular harm than oral anabolic steroids. Blood work from people running Anadrol or Winstrol typically shows HDL (the 'good' cholesterol that helps clear your arteries) dropping sharply, while LDL (the 'bad' stuff that builds plaque) rises. That pattern favors atherosclerosis.

The main reason is a single enzyme: hepatic lipase. Oral steroids are 17-alpha-alkylated to survive passing through the liver, and that heavy liver exposure pushes up production of hepatic lipase, whose main job is to break down HDL particles. In a 1989 crossover trial in 11 male weightlifters, oral stanozolol (6 mg/day for six weeks) raised hepatic lipase activity by 123%. HDL cholesterol fell 33%, the protective HDL2 subfraction fell 71%, and LDL rose 29%. So the often-quoted '50-70% drop' fits HDL2 better than total HDL, but this is a large shift within weeks. (The liver effects themselves are covered in our liver and kidney comparison.)

Injectable steroids can also mess with your lipids, but the mechanism is different and usually less severe. They largely bypass that first-pass liver metabolism, so the hepatic lipase spike isn't nearly as large. In the same trial, injected testosterone enanthate at a supraphysiological 200 mg/week lowered HDL by only 9% and actually lowered LDL by 16%.

The Real-World Risk Hierarchy

Not all anabolics carry the same cardiovascular risk. Some are merely risky. Others are hard to justify without close monitoring. The tiers below combine trial data, where it exists, with decades of user reports, so treat them as a rough ranking.

The strongest human evidence on long-term harm is a 2017 Circulation study of 140 experienced male weightlifters. The 86 men with at least two years of cumulative steroid use had weaker heart pumping than non-users (average ejection fraction 52% vs 63%) and more coronary plaque, which rose with years of use. It was cross-sectional, so it shows association rather than cause.

Tier 1: The Widowmakers

These are the compounds that carry the most cardiovascular risk. The primary culprits are the oral steroids we just discussed (Winstrol, Anadrol, Halotestin) and the non-aromatizing injectable, trenbolone.

• Oral Steroids: Mainly for their effect on the HDL/LDL ratio.
• Trenbolone: This one is a different case. It doesn't aromatize to estrogen, which users like for appearance, but estrogen is thought to be cardioprotective in men. Users commonly report sharp rises in blood pressure, and trenbolone is often blamed for cardiac hypertrophy (thickening of the heart muscle). Human data specific to trenbolone are sparse, so its reputation rests mostly on mechanism and user reports. The 'tren cough' some users describe right after injection is often called a vascular event, but its cause hasn't been established.

Tier 2: Handle With Care

Masteron and Equipoise belong here, along with high-dose testosterone. Masteron is a DHT derivative and, like trenbolone, doesn't convert to estrogen, so it can be harsh on lipids, just not to the degree of an oral. Testosterone is the baseline by which all others are measured. It can still raise blood pressure through water retention (via aromatization to estrogen) and thicken the blood by increasing red blood cell count (hematocrit), forcing your heart to work harder.

At replacement doses, the TRAVERSE trial (5,246 men aged 45-80 with low testosterone and high cardiovascular risk, 2023) found testosterone gel no worse than placebo for major cardiac events, though the testosterone group had more atrial fibrillation and pulmonary embolism. Those results don't carry over to the much higher doses lifters use.

SARMs: The 'Safer' Alternative That Isn't

SARMs were marketed as all the muscle-building of steroids with none of the side effects. That turned out to be wishful thinking, especially for cardiovascular health. While they don't seem to impact blood pressure or LDL as severely as traditional anabolics, they do consistently lower HDL.

In a 2013 placebo-controlled trial of LGD-4033 in 76 healthy men, 1 mg/day for 21 days cut HDL by roughly 40% and 0.3 mg/day by roughly 20%. LDL didn't change significantly, and HDL returned to baseline within five weeks of stopping. The authors noted that the clinical meaning of drug-induced HDL drops is unclear. For RAD-140 and most other SARMs sold online, we found no controlled human lipid data at all.

The other, more concerning issue is the lack of long-term data. We have decades of research on testosterone's effects. As of October 2026, we found no long-term cardiovascular outcome data for any SARM. Anyone telling you they're definitively safer is selling you something.

Peptides: A Different Set of Rules

This is where the conversation changes, though less completely than peptide marketing suggests. Most peptides used for performance and recovery work through pathways separate from the androgen receptor. They don't act on sex hormones or on the liver enzymes that drive steroid-related HDL loss. That doesn't make them cardiovascularly neutral, and most have very little human safety data.

• Growth Hormone Secretagogues (Ipamorelin, Tesamorelin, CJC-1295): These haven't shown the lipid damage seen with steroids, but calling them neutral overstates what's known. In its December 2024 safety review, FDA reported that 94% of participants in one 2006 CJC-1295 study had an adverse event after a single injection, including systemic vasodilatory reactions; other studies recorded low blood pressure and increased heart rate. FDA also described unpublished, anecdotal reports of a Phase 2 trial in HIV lipodystrophy that was terminated after a participant had a fatal heart attack 2 hours after their 11th weekly dose. The attending physician blamed undiagnosed coronary artery disease. As of October 2026, FDA's compounding safety page still lists increased heart rate and systemic vasodilatory reactions as serious adverse events for CJC-1295. The label for tesamorelin, an approved prescription medicine, says its long-term cardiovascular safety hasn't been established. Water retention, the most common complaint among users, can also nudge blood pressure up.

• Healing Peptides (BPC-157, TB-500): No cardiovascular harm has been documented, but that mostly reflects how little anyone has looked. As of October 2026, FDA says it has found no human exposure data for the TB-500 fragment and only limited safety information for BPC-157. Rodent studies suggest they work partly by modulating inflammation and promoting angiogenesis (the formation of new blood vessels); whether that helps or harms the heart in people hasn't been measured. A Phase 2 trial of full-length recombinant thymosin beta-4 in acute heart attack is registered (NCT07586865), but it tests the whole protein, not the TB-500 fragment sold online.

Melanotan II is the clearest outlier. FDA's compounding review cites published case reports of serious reactions, including a sympathomimetic toxidrome (a stimulant-like reaction that typically involves a racing heart and raised blood pressure). How often this happens in typical users isn't known.

Managing the Damage: A Practical Overview

Users of higher-risk compounds who follow harm-reduction guides commonly describe regular blood work as the bare minimum. The table below summarizes what they typically watch. It describes reported practice, not medical advice.

What We Still Don't Know

Oral steroids are in a class of their own for lipid damage, and long-term steroid use is linked to weaker heart function and more coronary plaque. What's missing is good data on heart attacks and deaths at the doses lifters actually use. SARMs lower HDL, but nobody knows yet what that means over decades.

For peptides, the data mostly don't exist. As of October 2026, no peptide in this comparison has long-term cardiovascular outcome data in healthy users, and the CJC-1295 Phase 2 death has never been published in detail. A different mechanism isn't the same as lower risk. For how these classes compare after a cycle ends, see our hormonal recovery comparison, and for other organ systems, the long-term effects overview.

Comparison table